Head-to-head evidence
Iloprost vs Ralinepag
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Hypertension
Shared mechanism: IP receptor (prostacyclin pathway) · full Hypertension pipeline
Iloprost · Ventavis
Marketed by Johnson & Johnson and partners
NCT01469169 · Phase 3 · completed
This was a small, single-group, open-label study with no randomized control or comparator arm, and its primary efficacy measure—change in pulmonary vascular resistance—was a hemodynamic surrogate rather than a direct clinical outcome. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Ralinepag
Developed by United Therapeutics
NCT03626688 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled trial with 687 participants, measuring time to a clinical worsening event as the primary endpoint. The sponsor reports a 55% reduction in the risk of clinical worsening for ralinepag versus placebo, a statistically significant result.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: December 2026 · NCT03683186 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Iloprost's landscape · Ralinepag's landscape